GZGuixi Zheng

Guixi Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guixi Zheng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Shichao Liu

    Department of Clinical Laboratory, Qilu Hospital of Shandong University , No. 107, Wenhua West Road, Lixia District, Jinan Shandong Province 250012

    2 shared publications
  • Shoucai Zhang

    Department of Clinical Laboratory, Qilu Hospital of Shandong University , No. 107, Wenhua West Road, Lixia District, Jinan Shandong Province 250012

    2 shared publications
  • Yingjie Liu

    Department of Clinical Laboratory, Qilu Hospital of Shandong University , No. 107, Wenhua West Road, Lixia District, Jinan Shandong Province 250012

    2 shared publications
  • Aimin Zhang

    Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, Baoding, People's Republic of China

    1 shared publication
  • Chuanxin Wang

    山东大学齐鲁医院 检验医学中心 (济南 250063)Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan 250063, China

    1 shared publication
  • Congbo Yue

    Clinical Laboratory of Qingdao Women and Children's Hospital Affiliated to Qingdao University, China

    1 shared publication

Latest Publications

  • The RNA-binding protein DDX39B promotes colorectal adenocarcinoma progression by stabilizing DCLK1

    by Shichao Liu, Shoucai Zhang, Hongxi Zhao, Yingjie Liu, Zeyu Zhang, Xueyan Geng, Maopeng Yin, Yongyuan Liang, Guixi Zheng

    DDX39B, a member of the DEAD-box (DDX) RNA helicase family, plays a pivotal role in the post-transcriptional regulation of diverse pathological processes, including tumor progression, viral replication, and neurodegenerative disorders. In this study, we investigated the functional significance of DDX39B in the proliferation and metastasis of colon adenocarcinoma (COAD) and sought to uncover its underlying molecular mechanism. Our findings revealed that DDX39B was markedly upregulated in COAD tumor tissues, and its elevated expression correlated with poor patient prognosis. Functional assays, both in vitro and in vivo, demonstrated that DDX39B substantially enhanced the proliferative and metastatic potential of COAD cells. Mechanistically, DDX39B expression was positively associated with Ki67 levels and was found to facilitate epithelial-mesenchymal transition (EMT) in COAD. As an RNA-binding protein (RBP), DDX39B increased the stability of DCLK1-B mRNA, a variant highly expressed in colorectal cancer known to promote cancer stemness, thereby augmenting its protein expression. Notably, silencing of DCLK1-B effectively abrogated the pro-metastatic effects induced by DDX39B overexpression. Collectively, our results offered novel insights into the oncogenic role of DDX39B and highlighted its potential as a therapeutic target in COAD.


  • Open Access

    Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma

    by Shoucai Zhang, Shichao Liu, Congbo Yue, Yingjie Liu, Guixi Zheng, Yi Zhang


  • Open Access

    Abstract 5010: Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment

    by Guixi Zheng

    Alternative splicing (AS) events play a crucial role in the tumorigenesis and progression of cancer. Transcriptome data and Percent Spliced In (PSI) values of ovarian cancer patients were downloaded from TCGA database and TCGA SpliceSeq. Totally we identified 1,472 AS events that were associated with survival of ovarian serous cystadenocarcinoma (OV) and exon skipping (ES) was the most important type. Univariate and multivariate Cox regression analysis were performed to identify survival-associated AS events and developed the prognostic model based on 11-AS events. The immune cells and different response to cytotoxic T lymphocyte associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) blockers in low-risk and high-risk group of OV patients were analyzed. Ten kinds of immune cells were found up-regulated in low-risk group. Activated B cell, natural killer T cell, natural killer cell and regulatory T cell were associated with survival of OV. The patients in low-risk group had good response to CTLA-4 and PD-1 blockers treatment. Moreover, a regulatory network was established according to the correlation between AS events and splicing factors (SFs). The present study provided valuable insights into the underlying mechanisms of OV. AS events that were correlated with the immune system might be potential therapeutic targets. Citation Format: Guixi Zheng. Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5010.

  • Open Access

    Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women

    by Yaping Tian, Chuanxin Wang, Liming Cheng, Aimin Zhang, Wen Liu, Lin Guo, Huiming Ye, Yanchun Huang, Jing Chen, Xinyu Wen, et al.

    To determine reference intervals for serum levels of human epididymis protein 4 (HE4) in Chinese women. In this multicenter (n = 9) study, 618 healthy women, 767 patients with non-malignant diseases, and 951 patients with malignant tumors were enrolled. Serum levels of HE4 were measured in all patients using electrochemiluminescence immunoassays. The influence of age, menopause, malignancy status and other characteristics on the levels of HE4 was evaluated using univariate and multivariate analyses. Confidence intervals (2.5–97.5 %) were determined in different populations. There were significant differences in HE4 levels among groups with different ages, menopause or malignancy status. Higher levels of HE4 were detected in elder compared to younger, post- compare to pre- menopause and malignant compared to benign subjects. Multivariate analysis showed that menopause and malignancy status, as well as smoking and pelvic masses were independent factors involved in serum HE4 levels. In pre-menopause stage, the reference ranges of HE4 level were 29.30–68.79, 28.12–1284.83 and 34.75–981.91 pmol/L in healthy, benign and malignant populations, respectively. In post-menopause stage, the reference ranges are 35.96–114.43, 39.11–2208.70 and 39.40–1678.13 pmol/L for those populations. The present study has established the reference intervals of HE4 levels in pre- and post-menopause populations with different malignancy status.